{"organizations": [], "uuid": "7a896eac054c4ad138cf38f3d16da0ffe38ca21b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-catalyst-pharmaceuticals-announces/brief-catalyst-pharmaceuticals-announces-enrollment-of-first-patient-in-phase-3-trial-of-firdapse-in-musk-antibody-positive-myasthenia-gravis-idUSASC09WHA", "country": "US", "domain_rank": 408, "title": "BRIEF-Catalyst Pharmaceuticals Announces Enrollment Of First Patient In Phase 3 Trial Of Firdapse In Musk Antibody Positive Myasthenia Gravis", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.47, "site_type": "news", "published": "2018-04-19T20:17:00.000+03:00", "replies_count": 0, "uuid": "7a896eac054c4ad138cf38f3d16da0ffe38ca21b"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-catalyst-pharmaceuticals-announces/brief-catalyst-pharmaceuticals-announces-enrollment-of-first-patient-in-phase-3-trial-of-firdapse-in-musk-antibody-positive-myasthenia-gravis-idUSASC09WHA", "ord_in_thread": 0, "title": "BRIEF-Catalyst Pharmaceuticals Announces Enrollment Of First Patient In Phase 3 Trial Of Firdapse In Musk Antibody Positive Myasthenia Gravis", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "neutral"}, {"name": "catalyst pharmaceuticals inc", "sentiment": "neutral"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 19 (Reuters) - Catalyst Pharmaceuticals Inc:\n* CATALYST PHARMACEUTICALS ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE 3 TRIAL OF FIRDAPSEÂ® IN MUSK ANTIBODY POSITIVE MYASTHENIA GRAVIS Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-19T20:17:00.000+03:00", "crawled": "2018-04-19T15:20:14.001+03:00", "highlightTitle": ""}